Literature DB >> 15367433

Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen.

Kanchan Rao1, Persis J Amrolia, Alison Jones, Catherine M Cale, Paru Naik, Doug King, Graham E Davies, H Bobby Gaspar, Paul A Veys.   

Abstract

The optimal approach to stem cell transplantation in children with immunodeficiency who lack a matched family donor is controversial. Unrelated donor stem cell transplantation gives equivalent outcome to mismatched family donor stem cell transplantation in severe combined immunodeficiency, whereas unrelated donors may be preferable in non-severe combined immunodeficiency children. However, unrelated donor stem cell transplantation with conventional conditioning regimens has been associated with significant treatment-related toxicity, particularly in non-severe combined immunodeficiency patients with preexisting organ dysfunction. We report the outcome of a series of 33 consecutive unrelated donor transplantations performed at our center in children with primary immunodeficiency using a reduced-intensity conditioning regimen between 1998 and 2001. We have compared these outcomes with a retrospective control cohort of 19 patients who underwent transplantation with myeloablative conditioning between 1994 and 1998. All children in both groups had primary engraftment. There was no statistical difference in the speed of immune reconstitution or incidence of graft-versus-host disease between the 2 groups. Overall survival was significantly better in the reduced-intensity conditioning group: 31 (94%) of 33 patients survived, compared with 10 (53%) of 19 in the myeloablative conditioning group (P = .014). We conclude that the reduced-intensity conditioning regimen results in improved survival and reduced transplantation-related mortality compared with myeloablative conditioning in high-risk patients undergoing unrelated donor transplantation.

Entities:  

Mesh:

Year:  2004        PMID: 15367433     DOI: 10.1182/blood-2004-03-0960

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

Review 1.  Chronic granulomatous disease: lessons from a rare disorder.

Authors:  Brahm H Segal; Paul Veys; Harry Malech; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

2.  Successful nonmyeloablative bone marrow transplantation for leukocyte adhesion deficiency type I from an unrelated donor.

Authors:  Masahiro Tokunaga; Koichi Miyamura; Haruhiko Ohashi; Naruhiko Ishiwada; Seitaro Terakura; Miyoko Ikeguchi; Yachiyo Kuwatsuka; Yoshihiro Inamoto; Taku Oba; Shigeru Tsuchiya; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 3.  History and current status of newborn screening for severe combined immunodeficiency.

Authors:  Antonia Kwan; Jennifer M Puck
Journal:  Semin Perinatol       Date:  2015-04-30       Impact factor: 3.300

Review 4.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Authors:  Jennifer Heimall; Jennifer Puck; Rebecca Buckley; Thomas A Fleisher; Andrew R Gennery; Benedicte Neven; Mary Slatter; Elie Haddad; Luigi D Notarangelo; K Scott Baker; Andrew C Dietz; Christine Duncan; Michael A Pulsipher; Mort J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-06       Impact factor: 5.742

5.  Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.

Authors:  Justin T Wahlstrom; Christopher C Dvorak; Morton J Cowan
Journal:  Curr Pediatr Rep       Date:  2015-03-01

Review 6.  Long term outcomes of severe combined immunodeficiency: therapy implications.

Authors:  Jennifer Heimall; Morton J Cowan
Journal:  Expert Rev Clin Immunol       Date:  2017-09-23       Impact factor: 4.473

7.  Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.

Authors:  M Oda; K Isoyama; E Ito; M Inoue; M Tsuchida; H Kigasawa; K Kato; S Kato
Journal:  Int J Hematol       Date:  2009-03-18       Impact factor: 2.490

8.  Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.

Authors:  Linda M Griffith; Morton J Cowan; Donald B Kohn; Luigi D Notarangelo; Jennifer M Puck; Kirk R Schultz; Rebecca H Buckley; Mary Eapen; Naynesh R Kamani; Richard J O'Reilly; Robertson Parkman; Chaim M Roifman; Kathleen E Sullivan; Alexandra H Filipovich; Thomas A Fleisher; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2008-11-06       Impact factor: 10.793

9.  Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency.

Authors:  Brandon M Triplett; Chong Wang; Jie Yang; Mari Dallas; Christine Hartford; Vanessa Howard; Asha Pillai; David Shook; Ashok Srinivasan; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-27       Impact factor: 5.742

10.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.